Skip to content
Teva Pharmaceutical (TEVA) is not a company immune to controversy, but one long standing overhang might have just been removed.Last week, the global generics pharma company announced the launch of the first FDA-approved generic versions of Gilead Sciences' HIV treatments Truvada and Atripla.The launch brings to an end a patent case which stretches back to September 2018, one which Raymond James analyst Elliot Wilbur calls “one of the lengthier PIV battles in recent memory.”In addition to being able to tap into a lucrative market - Truvada generated global sales of $753 million in the first half of 2020, while Atripla snagged a more modest $176 million – Teva has an opportunity to establish its new offerings ahead of anticipated competition.“While we expect other generic filers are not far behind in entering this market (there are at least 9 other filers on Truvada),” Wilbur noted, “Teva’s earlier settlement at least gives the...
The world’s last major onshore oil discovery could be made in a country where no oil has ever been produced, and the upside potential for the company that exploits it should be remarkable...
With the ramping up of global 5G networks, Nokia (NOK) is staking a claim to be one of the field’s main players. The Finnish company was once one of the world’s leading mobile phone makers, but that was long ago and over recent years has reinvented itself as a telecom equipment provider. The move appears to be paying off as it has just notched its 100th 5G deal.While Raymond James analyst Simon Leopold considers hitting the milestone as “great progress,” the analyst has reservations about Nokia becoming one of the leaders in an industry expected to boom as the new decade progresses.“We continue to regard 5G as an investment theme, but with the recent loss at Verizon, Nokia's Mobility unit continues to face challenges,” the 4-star analyst said. “We will monitor progress with its expanding chip portfolio (Reef Shark) and look forward to hearing from the new CEO regarding his vision...
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]...
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]...
Canadian cannabis company Aurora Cannabis (ACB) has never earned an operating profit, nor generated any operating cash flow, either. Instead, for every year of its existence, its losses have mounted, and its cash burn rate increased, culminating in a $356 million operating loss ($2.4 billion, net) and $509 million in cash burnt over the last 12 months.Nevertheless, hope that Aurora Cannabis might one day be profitable springs eternal, and BMO analyst Tamy Chen set out to figure out when that day might arrive, conducting "an analysis to assess when ACB could achieve sustainable profitability."Her findings may surprise you.Even assuming Aurora does not cut its selling, general, and administrative (SG&A) spending in any "meaningful" way, Chen believes that Aurora Cannabis might successfully sell enough marijuana over the next three years to eventually achieve "EBITDA" profitability (which we'd remind you, is not at all the same thing as GAAP net profitability).Still, based on...
Hendrickson Truck Commercial Vehicle Systems is offering a comprehensive premium rear suspension portfolio as a part of the chassis enhancements of the new Western Star 49X. ...
